This updated version of AVAC’s 3D graphic shows priorities across the research-to-rollout spectrum. The graphic appears in AVAC Report 2014/15: Prevention on the Line.
Essential Actions for HIV Prevention Research Rollout 2014/15
What do women want in multipurpose technologies?
Multipurpose Prevention Technologies (MPTs) are a fast-growing area in women’s sexual and reproductive health. On November 12, AVAC and CAMI Health co-hosted a webinar: MPT Acceptability in Uganda, Nigeria and South Africa.
FY2015 US Global AIDS Budget Plan: The Human Impact
The US government’s efforts to fight the global AIDS pandemic through both the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to Fight AIDS, Tuberculosis and Malaria have been transformative in the global AIDS response. To maintain the current total level of US global HIV/AIDS funding in Fiscal Year 2015, the US House of Representatives has proposed restoring US$300 million in PEPFAR funding. As illustrated in this infographic, amfAR has estimated the potential human impact of US$300 million to expand lifesaving HIV prevention, Treatment U=U and care services.
PrEP by the Numbers: Efficacy, regulatory approval and more
PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.
The Number of Microbicide Trials Currently Underway
This graphic from AVAC’s Microbicides by the Numbers one-pager shows the number of ongoing microbicide trials in each phase of study.
Increasing National Impact and Uptake of Good Participatory Practice Guidelines for Biomedical HIV Prevention (GPP): Three Country Case Studies
GPP provides a systematic framework for stakeholder engagement. This infographic examines how GPP was applied to the national trial oversight process in three countries: Uganda, Thailand, and South Africa. The timline plots key GPP activities and milestones from 2011-2014. This poster was presented at the 2014 HIV Research for Prevention conference in South Africa.
The Tipping Point: Moving From Rhetoric to Real Milestones for Ending AIDS
One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. This poster was presented at the 2014 HIV Research for Prevention Conference in South Africa.
Tracking Investments and Expenditures in HIV Prevention Research and Development: Sustaining Funding in a Shifting International Development Landscape
This infographic shows the shifting landscape of HIV R&D. It emphasizes that funding is decreasing and that priorities are changing. This poster was presented in 2014 at the HIV Research for Prevention (R4P) conference in South Africa.
Innovation in Stakeholder Engagement: Piloting a Monitoring and Evaluation Toolkit
The M&E toolkit was developed to better understand and assess the impact of engagement on clinical trials and communities. The tools and web-based analysis database were piloted in South Africa and Kenya. This poster, presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa, outlines the process and lessons learned.
Resource Tracking to Ensure Accountability and Sustainability: HIV Prevention, Treatment U=U, Diagnostics and Cure Research Investment Analysis
This infographic explains how AVAC tracks HIV expenditures and investments. This has resulted in accurate and consistent year-to-year comparisons of grants and investment figures. This poster was presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa.